Press Releases

 
Press Releases
  Date Title and Summary View
Feb 5, 2014
Fremont, California, February 5, 2014 /PRNewswire/ — Zosano Pharma, Inc., (Zosano) announced today that it has entered into an agreement with Novo Nordisk A/S (NVO) to develop a new transdermal presentation of semaglutide, an investigational proprietary human GLP-1 (Glucagon-Like Peptide-1) analogue, to be administered once weekly using Zosano...
May 14, 2013
Fremont, CA — May 14, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the compan...
Apr 15, 2013
Fremont, CA — April 15, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos, Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics ...
Apr 9, 2013
Fremont, CA — April 9, 2013 — Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today that Chris Krueger has been appointed as the company's Chief Business Officer. In this position, Mr. Krueger will be responsible for the company's business devel...
Oct 11, 2011
FREMONT, Calif. and TOKYO, Oct. 10, 2011 /PRNewswire/ — Zosano Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) announced today that they have entered into a long–term strategic collaboration for the development, commercialization and supply of a weekly transdermal patch formulation of Teribone™ (teriparatide acet...
Jan 20, 2010
Fremont, Calif. January 20, 2010 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Dr. Peter Daddona, the company’s chief scientific officer, will present at the 14th Annual Drug Delivery Partnerships Meeting in Orlando, Florida ...
Nov 9, 2009
Fremont, Calif. –  November 9, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products using  a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-...
Jul 7, 2009
Fremont, Calif. – July 7, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that the company has closed a new round of financing in the amount of $30 million.Nomura Phase4 Ventures led the round and all of the ...
Jun 11, 2009
Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten von Stein, MD, PhD has joined the company as Chief Medical Officer.  Dr. von Stein reports to Zosano Chair and CEO, Gail Sc...
Jun 11, 2009
Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten von Stein, MD, PhD has joined the company as Chief Medical Officer.  Dr. von Stein reports to Zosano Chair and CEO, Gail Sc...
Page: FirstPrevious ...
8
NextLast
= add release to Briefcase